NervGen Pharma priced a public offering of 24 million units at $2.50 each, with each unit consisting of one common share and one warrant to buy another share. The deal implies gross proceeds of about $60 million before fees and expenses. The announcement is financing-related and should be modestly relevant to the stock but is otherwise routine for a clinical-stage biotech.
NervGen Pharma priced a public offering of 24 million units at $2.50 each, with each unit consisting of one common share and one warrant to buy another share. The deal implies gross proceeds of about $60 million before fees and expenses. The announcement is financing-related and should be modestly relevant to the stock but is otherwise routine for a clinical-stage biotech.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
